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or patients with moderate to severe psoriasis, long-term treatment is usually required for adequate disease control. [1] [2] [3] [4] Conventional systemic therapies have been used for decades, but long-term usage is sometimes associated with organ-specific toxicity. 5, 6 Current biologic therapies have improved clinical management of psoriasis because of a favorable benefit-risk balance without cumulative organ-specific toxicity. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Recently published data from randomized trials involving the anti-interleukin (IL)-17A monoclonal antibodies, secukinumab, 17, 18 ixekizumab, 19, 20 and brodalumab, 21, 22 raised expectations for improved management of psoriasis. However, as with any new Inte-grated Analysis Set data were used to make comparisons between ixekizumab and placebo, and Psoriasis Placeboand Active-Controlled Integrated Ana-lysis Set data were used to make comparisons between ixekizumab and etanercept. The Psoriasis Maintenance Integrated Analysis Set comprised ixekizumab responders from the UNCOVER-1 and -2 induction periods who were re-randomized at week 12 to either maintenance treatment or treatment withdrawal to week 60. Data in the All Psoriasis Ixekizumab Exposures Analysis Set, which integrates all ixekizumab doses and study periods, were pooled from 7 clinical trials (Supplementary  Table I) . 19, 20, [23] [24] [25] [26] Data cut-off was April 9, 2015. Protocols received ethical review board approval; patients gave written informed consent.
Safety evaluations
The safety population consisted of all randomized patients receiving 1 or more doses of study treatment. The Maintenance Dosing Period Primary Population consisted of all re-randomized patients receiving 1 or more doses of study treatment during the maintenance period. Adverse events (AEs) were classified based on the Medical Dictionary for Regulatory Activities versions 17.0 (Primary Psoriasis Placebo-Controlled Integrated Analysis Set and Psoriasis Placebo-and Active-Controlled Integrated Analysis Set) and 17.1 (Psoriasis Maintenance Integrated Analysis Set and All Psoriasis Ixekizumab Exposures Analysis Set). A treatment-emergent AE (TEAE) was an event first occurring or worsening in severity after baseline and on or before the last day within the treatment period. Lowest level terms were used for the TEAE computation and preferred terms are presented. Exposure-adjusted incidence rates (IRs) for TEAEs represent the number of patients with a particular event per 100 patient-years (PY) of exposure. Time during the treatment period was considered entire exposure time. If an event occurred multiple times for a patient, the event was counted once.
Neutropenia was defined as Common Terminology Criteria for AE grade 2 or greater (absolute neutrophil count \1.5 3 10 9 /L). Infection events with onset date 14 days or less before or after the grade-2 neutrophil count collection date were considered infections preceded or accompanied by neutropenia.
Data for inflammatory bowel disease (IBD) are presented as reported by the investigator, not as adjudicated. Adjudicated data will be presented in a future publication.
Statistical methods
Treatment comparisons for frequencies were analyzed using the Cochran-Mantel-Haenszel test stratified by study.
27 A Poisson regression model (treatment as explanatory variable) was used to compare exposure-adjusted IRs.
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In the induction period, statistical comparisons between ixekizumab and placebo were conducted within Primary Psoriasis Placebo-Controlled Integrated Analysis Set, and statistical comparisons between ixekizumab and etanercept were conducted within the Psoriasis Placebo-and Active-Controlled Integrated Analysis Set. Statistical tests with 2-sided P values less than .05 were considered statistically significant.
RESULTS

Patients and exposure
Overall, 4209 patients received 1 or more doses of ixekizumab with a total exposure of 6480 patientyears (median 507 days; maximum 1794 days) (Fig 1 and Table I ). Supplementary Table II During induction, incidence rates per 100 patient-years of most adverse events of special interest were comparable in the ixekizumab and etanercept groups.
Overall safety
Induction period: ixekizumab versus etanercept (Psoriasis Placebo-and Active-Controlled Integrated Analysis Set; UNCOVER-2 and -3). The IRs of TEAEs were similar in the ixekizumab groups and the etanercept group (Supplementary  Table III ; Supplementary Appendix for Primary Psoriasis Placebo-Controlled Integrated Analysis Set). Most TEAEs were mild or moderate. The overall safety profile of etanercept was comparable with ixekizumab. The most common TEAE type was infection. The IRs of infections were significantly higher in the total ixekizumab group than in the etanercept group, but this was not true for individual infection types. The IRs of injection-site reactions (ISRs) were similar in ixekizumab-and etanercepttreated patients. However, among individual types of ISRs, the IR of injection-site pain was higher in patients treated with ixekizumab every 2 weeks compared with etanercept-treated patients, and the IR of injection-site erythema was lower in patients treated with ixekizumab every 4 weeks compared with etanercept-treated patients.
The IRs of serious AEs (SAEs) and discontinuations because of AEs did not significantly differ between the ixekizumab and the etanercept groups (Supplementary Table III ). The IRs of individual SAEs and discontinuations because of AEs were also similar in the ixekizumab and etanercept groups. No deaths occurred during the induction period.
Maintenance period (Psoriasis Maintenance Integrated Analysis Set; ixekizumab only). During maintenance, no significant differences were observed in the IRs of TEAEs between groups taking ixekizumab every 4 weeks and every 12 weeks (Supplementary Table IV) . Most TEAEs were mild or moderate (Supplementary Table IV) . Nasopharyngitis was the most common TEAE with ixekizumab. SAEs occurring in 2 or more patients in the total ixekizumab group were falls, coronary artery disease, inguinal hernia, osteoarthritis, and intervertebral disc protrusion. In the total ixekizumab group, the IRs of discontinuations because of AE were low; the most common reasons were related to protocol-mandated discontinuation of patients with positive tuberculosis (TB) test results. However, there were no cases of clinically active or reactivated TB. Two deaths occurred in the maintenance period (Supplementary Table V) . and were then re-randomized in the maintenance period were included in PsM (UNCOVER-1 and -2).
All Psoriasis Ixekizumab Exposures Analysis Set. Supplementary Table VI Table V) ; the majority of deaths were a result of cardiovascular events.
AEs of special interest
Infections were most often nonserious, mild, or moderate infections of the upper respiratory tract. The IRs of serious infections were similar in the ixekizumab groups and the etanercept group during the induction period (Fig 2, A, and Supplementary Table VII); erysipelas (n = 2) was the only serious infection reported by 1 or more ixekizumab-treated patient. No serious infection occurred in more than 1 ixekizumab-treated patient in the Psoriasis Maintenance Integrated Analysis Set. Cellulitis (n = 17; 0.4%) was the most common serious infection in the All Psoriasis Ixekizumab Exposures Analysis Set. The frequencies of infections were not greater for ixekizumab-treated patients compared with placebo-treated patients with preceding or accompanying neutropenia grade 2 or higher.
In the All Psoriasis Ixekizumab Exposures Analysis Set, 36 ixekizumab-treated patients had positive TB test results, and 13 patients were reported to have latent TB during yearly evaluation (Supplementary Table VI ). There were no cases of clinically active or reactivated TB in ixekizumab clinical trials.
There were no invasive fungal infections involving candidemia or deep organ infection identified in any treatment period, nor were there discontinuations because of Candida infections. Of 165 (2.5 per 100 PY) reported Candida cases in the All Psoriasis Ixekizumab Exposures Analysis Set (Fig  2, B , and Supplementary Table VII), 5 (0.1% of all patients) were assessed by the investigator as severe. In over 80% of all patients with Candida-related events, infection(s) had either resolved or were resolving by database lock per investigator judgement. The most frequently occurring Candida infections included vulvovaginal candidiasis (2.4 per 100 PY) and oral candidiasis (1.2 per 100 PY) (Fig 2, C ) .
During the induction period, the IRs of oral candidiasis were 0 per 100 PY in placebo group, 0.6 per 100 PY in the etanercept and ixekizumab every 4 weeks groups, and 3.6 per 100 PY in the ixekizumab every 2 weeks group (Fig 2, C ) . In the All Psoriasis Ixekizumab Exposures Analysis Set, the median duration of oral Candida infections was 5 weeks; of 78 patients, 3 had a severe event. Among all patients, 8 cases (0.1 per 100 PY) of esophageal candidiasis were reported in patients either receiving or recently administered ixekizumab; of these, 2 were SAEs and 4 were confirmed with esophagogastroduodenoscopy. Most patients with esophageal candidiasis received oral fluconazole alone or with other agents. In all cases, the events resolved, and the patients remained on study.
The IRs of nonmelanoma skin cancers (NMSC) and malignancies excluding NMSC were low (Fig 2,  D and E, and Supplementary Table VII) . Of malignancies excluding NMSC, there was no pattern of tumor type (Supplementary Table VIII ). In all, 22 patients had malignancies leading to discontinuation; no patient with NMSC discontinued.
Overall, the incidences of reported Crohn's disease (Fig 2, F ) and ulcerative colitis ( for MACE because adjudication was only performed for the phase (Ph) III trials. I, Injection-site reactions (composite of injection site reactionerelated terms). ETN, Etanercept; IXE, ixekizumab 80 mg; LTE, long-term extension; Ps, psoriasis; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks; RCT, randomized-controlled trial; WD, withdrawal.
J AM ACAD DERMATOL VOLUME 76, NUMBER 3 developed these conditions. In the All Psoriasis Ixekizumab Exposures Analysis Set, 3 and 5 ixekizumab-treated patients discontinued because of Crohn's disease and ulcerative colitis, respectively. There were 4 patients with pre-existing Crohn's disease, none of whom reported an exacerbation during the trials, and 10 patients with pre-existing ulcerative colitis at enrollment, 4 of whom had flares during study participation. During the induction period, the between-group rates of adjudicated major adverse cardiovascular events (MACE) were similar (Fig 2, H ) . The MACE individual components did not change substantially with longer exposure to ixekizumab. In the All Psoriasis Ixekizumab Exposures Analysis Set, the IR of adjudicated MACE was 0.6 per 100 PY (median time to onset 254.0 days). Of 4035 ixekizumab-treated patients participating in trials with independent MACE adjudication, 7 patients experienced vascular death (Supplementary Tables  V and VIII) . With the exception of 1 nonfatal stroke, all MACE were SAEs. At baseline, patients subsequently developing treatment-emergent MACE had a higher prevalence of established risk factors for acute atherothrombotic events than patients without MACE. After adjustment for exposure, ixekizumab treatment during the maintenance period was not associated with clinically meaningful changes in blood pressure, body weight, blood glucose, or proatherogenic lipid profile compared with placebo.
There were no completed suicides in the All Psoriasis Ixekizumab Exposures Analysis Set. The rate of suicidal ideation or behavior observed was 1.39 per 1000 patient-years; Supplementary Table VIII lists depression-and self-injury-related TEAEs occurring in 1 or more patients. The IRs of these events were similar between ixekizumab treatment groups. In the All Psoriasis Ixekizumab Exposures Analysis Set, there were 8 reported suicide attempts; 2 additional events were considered by the sponsor to be suicide attempts, 1 of which occurred during patient follow-up 2 months after the last dose of ixekizumab. Only patients with 1 or more risk factors attempted suicide; 2 patients had undisclosed history of suicide attempts, a study exclusion criterion. Depression-and self-injury-related events also occurred in patients treated with placebo (1 suicide attempt in the phase I study, which is not included in the integrated data sets) and etanercept (1 suicidal ideation).
During the induction period, the IRs of ISRs were similar in the total ixekizumab and etanercept groups (Fig 2, I ). Most ISRs in ixekizumab-treated patients were mild or moderate in severity, and 53.1% of patients experiencing ISRs had only 1 occurrence during induction. In the All Psoriasis Ixekizumab Exposures Analysis Set, the median time to occurrence from the first dose to first occurrence of ISR was 14 days. The median duration of ISRs was 2.03 days. Eight ixekizumabtreated patients discontinued because of ISRs. There were no confirmed cases of ixekizumabrelated anaphylaxis events.
DISCUSSION
With 6480 patient-years of exposure in 4209 patients, we evaluated long-term continuous follow-up in one of the largest cohorts of patients with psoriasis treated with an antieIL-17A monoclonal antibody in a clinical trial setting. Most observed AEs were nonserious and did not lead to treatment discontinuation.
The safety profile reported here is consistent with previous reports for ixekizumab. 19, 20 In analyses presented here, IRs are based on numbers of patients with events per 100 patient-years of exposure, with entire time on treatment considered the exposure time. Ixekizumab-treated patients, compared with etanercept-and placebo-treated patients, did not show evidence of an increased risk of suicidal thoughts and behaviors.
In the 2 trials including etanercept (UNCOVER-2 and -3), the 12-week safety profile for ixekizumab was comparable with that of etanercept with some exceptions. A limitation of our data is that direct comparison between ixekizumab and etanercept can be made only for the 12-week induction period. A difference was an increased incidence of oral candidiasis infections with ixekizumab. This is consistent with a proposed role of IL-17 in host defense against extracellular pathogens, including fungi such as the yeast Candida albicans.
29-32 The use of ixekizumab was not associated with an overall increased frequency of serious infections (including TB and invasive fungal infections) during induction. The rate of suicidal ideation or behavior observed among patients with psoriasis who were exposed to ixekizumab was 1.39 per 1000 patient-years, which is within the range reported for patients with psoriasis.
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In conclusion, no unexpected safety signals were observed during maintenance with ixekizumab. Long-term extension studies are ongoing. 
SUPPLEMENTARY APPENDIX
Induction period: ixekizumab versus placebo (Primary Psoriasis Placebo-Controlled Integrated Analysis Set; UNCOVER-1,e2, and -3).
During the 12-week induction period, the incidence rates of patients experiencing 1 or more treatment-emergent adverse event (AE) were higher in the ixekizumab every 2 week and every 4 week groups compared with the placebo group. 20 Most treatment-emergent AEs were mild or moderate. Among individual treatment-emergent AEs occurring in 1% or more of patients in the total ixekizumab group, there were higher incidences of injection-site reactions, nausea, and oropharyngeal pain in the total ixekizumab group compared with the placebo group.
The incidence rates for patients with 1 or more serious AEs and discontinuations because of AEs did not significantly differ between the ixekizumab and placebo groups. 20 The most common AE leading to discontinuation were injection-site reactions in ixekizumab groups and worsening psoriasis in the placebo group. z TEAEs listed are those that appeared at $5/100 PY in the total IXE treatment group in both studies combined.
x SAEs listed are those that appeared in $2 patients in the total IXE treatment group in both studies combined. k AEs listed are those that appeared in $2 patients in the total IXE treatment group in both studies combined; includes death. Exposure-adjusted IR for treatment-emergent adverse events represent the number of patients with a particular event/100 PY of exposure. Time during the treatment period was considered entire exposure time. Medical Dictionary for Regulatory Activities preferred terms under groupings are presented. ETN, Etanercept; IR, incidence rate; IXE, ixekizumab; MACE, major adverse cardiovascular events; MI, myocardial infarction; N, number of patients in the analysis population; n, number of patients with at least 1 event in the specified category; NMSC, nonmelanoma skin cancer; PBO, placebo; PY, patient-years; Q2W, every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk. *In addition to the listed treatment-emergent adverse events, the following additional treatment-emergent adverse events occurred in 1 patient each in the all psoriasis data set: alcoholism, drug dependence, dysphoria, dyssomnia, emotional distress, intentional overdose, major depression, memory impairment, poor quality sleep, and substance abuse. y There was 1 suicide attempt in the phase I study, which was not counted in the Psoriasis Placebo-and Active-Controlled Integrated Analysis Set database. z In addition to the listed treatment-emergent adverse events, the following additional treatment-emergent adverse events occurred in 1 patient each in the all psoriasis data set: vulval cancer, metastatic prostate cancer, breast cancer, lip squamous cell carcinoma, malignant lung neoplasm, metastases to liver, metastases to lung, malignant neoplasm, metastatic nonsmall cell lung cancer, rectal adenocarcinoma, rectal cancer, renal cancer stage II, renal cell carcinoma, renal neoplasm, squamous cell carcinoma, squamous cell carcinoma of lung, synovial sarcoma, tonsillar neoplasm, and transitional cell carcinoma. These reported events were adjudicated as nonfatal MIs.
Supplementary
zz Nonfatal stroke includes ischemic, hemorrhagic, and unknown stroke type.
